Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | CAD | P27708 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11223928 | 1.00 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL4534897 | 1.00 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL1553115 | 1.00 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL459507 | 1.00 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| SCHEMBL366162 | 0.98 | — | — | |
| SCHEMBL818996 | 0.98 | — | — | |
| SCHEMBL367679 | 0.98 | — | — | |
| SCHEMBL31615213 | 0.95 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| Water SCHEMBL5917424 | 0.95 | ALOX15 (0.44) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL16223251 | 0.93 | ALOX15 (0.42) | ALOX15ALDH1A1LMNAHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899180-A | Chiral oxazoline diester derivative and preparation method and application thereof | 安徽农业大学 | 2025-04-29 | — | — | CN | claimed |
| CN-114853634-A | Nicotinyl alcohol ether derivative, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2022-08-05 | — | — | CN | claimed |
| CN-102388017-A | A method of synthesising an amino acid derivative of azelaic acid | MALAYSIAN PALM OIL BOARD | 2012-03-21 | — | — | CN | claimed |
| WO-2010117258-A1 | A METHOD OF SYNTHESISING AN AMINO ACID DERIVATIVE OF AZELAIC ACID | MALAYSIAN PALM OIL BOARD (MY) | 2010-10-14 | — | — | WO | claimed |
| CN-100445273-C | Calixarene aza-crown ether derivative, its preparation and use as metal ion fluorescent identification agent | UNIV BEIJING NORMAL (CN) | 2008-12-24 | — | — | CN | claimed |
| CN-1982300-A | Calixarene aza-crown ether derivative, its preparation and use as metal ion fluorescent identification agent | UNIV BEIJING NORMAL (CN) | 2007-06-20 | — | — | CN | claimed |
| EP-1592715-A1 | WATER SOLUBLE AND BIOCOMPATIBLE GELS OF HYALURONIC ACID CROSS-LINKED WITH BI-FUNCTIONAL L-AMINOACIDS OR L-AMINOESTERS | Biosphere S.p.A. (IT) | 2005-11-09 | — | — | EP | claimed |
| WO-2004067575-A1 | WATER SOLUBLE AND BIOCOMPATIBLE GELS OF HYALURONIC ACID CROSS-LINKED WITH BI-FUNCTIONAL L-AMINOACIDS OR L-AMINOESTERS | BIOSPHERE S.P.A. (IT) | 2004-08-12 | — | — | WO | claimed |
| EP-4673451-A1 | POLYMERIZABLE MONOMER | Universität Linz (AT) | 2026-01-07 | — | — | EP | disclosed |
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20250270184-A1 | PROCESSES FOR THE PREPARATION OF FINERENONE | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| EP-3338849-B1 | BALLOON WRAPPING APPARATUS AND BALLOON WRAPPING METHOD | TERUMO CORP (JP) | 2025-06-25 | — | — | EP | disclosed |
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025093456-A1 | THIAZOLIDINE-4-CARBOXYLATE PROPERFUMES | FIRMENICH SA (CH) | 2025-05-08 | — | — | WO | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0153992-B1 | WATER SOLUBLE DERIVATIVES OF 3,5-DIACETO AMIDO-2,4,6-TRIIODOBENZOIC ACID AND PROCESS FOR THEIR PREPARATION AND USE | Dr. Franz Köhler Chemie GmbH (DE) | 1991-10-16 | — | — | EP | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
| US-4607123-A | X-RAY CONTRAST AGENTS | DR. FRANZ KOHLER CHEMIE GMBH (DE) | 1986-08-19 | — | — | US | disclosed |
| EP-0153992-A2 | Water soluble derivatives of 3,5-diaceto amido-2,4,6-triiodobenzoic acid and process for their preparation and use | Dr. Franz Köhler Chemie GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
| US-4256748-A | INOTROPIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | GAA 537/4885ALOX15 1414/4885ALDH1A1 1343/4885 |
| US-20250270184-A1 | PROCESSES FOR THE PREPARATION OF FINERENONE | CYP11B1, CYP11B2, HSD17B7 | GAA 2587/4885ALOX15 911/4885ALDH1A1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.